Clinical trials: Metastatic Solid Tumor Cancer
Solid Tumor, Adult
Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors
The main purpose of this first-in-human study of GEN1056, is to evaluate safety. In addition, the study will determine the recommended dose and frequency for subsequent clinical studies and will assess the preliminary anti-tumor…
- Trial name
- NCT05586321
- Testing
- GEN1056
- Where
- 7 sites in Georgia, Moldova and 1 more
- Volunteers
- 26 people
- Sponsor
- Genmab
HER2-positive Breast Cancer, HER2-positive Gastric Cancer
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
A Phase 1b, open-label, dose escalation study of PRS-343 in combination with atezolizumab in patients with HER2-positive advanced or metastatic solid tumors.
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Bladder Cancer, HER2-positive Solid Tumor
- Trial name
- NCT03650348
- Testing
- PRS-343 in Combination with Atezolizumab
- Where
- 8 sites in United States
- Volunteers
- 41 people
- Sponsor
- Pieris Pharmaceuticals, Inc.
Solid Tumors, Metastatic Cancer
Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors
The aim of this research is to evaluate the potential interest of an association of Pazopanib, a multi-tyrosine kinase inhibitor, and cisplatin.
- Trial name
- PACIFIK (NCT01165385)
- Testing
- cisplatin, Pazopanib
- Where
- 5 sites in France
- Volunteers
- 35 people
- Sponsor
- UNICANCER
Metastatic Cancer, Cancer
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
The goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer.
- Conditions
- Metastatic Cancer, Cancer, Solid Tumors
- Trial name
- NCT01300533
- Testing
- BIND-014
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- BIND Therapeutics
Neoplasms, Triple-Negative Breast Cancer
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06647263 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT02078752
- Testing
- PF-06647263
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Pfizer
Neuroblastoma in Children, Neuroblastoma, Recurrent, Refractory
Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
This is an Expanded Access Program (EAP) that will give the participants access to the drug SL-28 before it is approved by the FDA.
- Conditions
- Neuroblastoma in Children, Neuroblastoma, Recurrent, Refractory, Advanced Cancer, Advanced Malignant Neoplasm
- Trial name
- NCT06872489
- Testing
- SL-28.
- Sponsor
- Second Life Therapeutics
Anxiety, Depression
Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies
This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started…
- Conditions
- Anxiety, Depression, Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT07336238
- Testing
- Psychotherapy, Psilocybin, Survey Administration
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Washington
Advanced/Metastatic Solid Tumors
A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients
This is a Phase 1, open-label, dose escalation study in patients with advanced/metastatic solid tumors. Study drug, ADG116, is an anti -CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4.
- Trial name
- NCT04501276
- Testing
- ADG116, ADG106, anti PD1 drug
- Where
- 4 sites in United States, Australia
- Volunteers
- 72 people
- Sponsor
- Adagene Inc
Advanced Cancer, Gastric Cancer
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
This Phase I/Ib study is a Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine, Given Orally on a Daily Schedule in Patients…
- Conditions
- Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer
- Trial name
- GEN602 (NCT03775525)
- Testing
- GZ17-6.02, Capecitabine
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Genzada Pharmaceuticals USA, Inc.
Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
This phase I trial studies the side effects and best dose of pembrolizumab and recombinant interleukin-12 in treating patients with solid tumors.
- Trial name
- NCT03030378
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 27 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced (Unresectable) or Metastatic Solid Tumors
A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
This is a first in human (FIH), Phase 1, dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion portion (Part B).
- Trial name
- NCT07612176
- Testing
- NEOK001, NEOK001 RDE
- Where
- 9 sites in United States
- Volunteers
- 155 people
- Sponsor
- NEOK Bio, Inc.
Advanced Solid Tumors, Metastatic Colon Cancer
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers
An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability, and PK of fruquintinib in patients with advanced solid tumors, metastatic colorectal cancer and metastatic breast cancer.
- Conditions
- Advanced Solid Tumors, Metastatic Colon Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer
- Trial name
- NCT03251378
- Testing
- Fruquintinib (HMPL-013)
- Where
- 9 sites in United States
- Volunteers
- 129 people
- Sponsor
- Hutchison Medipharma Limited
Breast Cancer, Lung Cancer
Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
The purpose of this study is to test the combination of an experimental drug known as MGCD0103 given along with an FDA-approved drug called docetaxel.
- Conditions
- Breast Cancer, Lung Cancer, Pulmonary Cancer, Non-Small-Cell Lung Carcinoma
- Trial name
- NCT00511576
- Testing
- MGCD0103 & Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Mirati Therapeutics Inc.
Advanced Solid Tumors
A Study of ASP1002 in Adults for Treatment of Solid Tumors
ASP1002 is being studied in people with tumors that have spread to nearby tissue (locally advanced) that cannot be removed by surgery (unresectable) or tumors that have spread to other parts of the body (metastatic).
- Trial name
- NCT05719558
- Testing
- ASP1002, Bevacizumab, Oxaliplatin
- Where
- 15 sites in United States
- Volunteers
- 798 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
This phase II trial studies the effect of avapritinib in treating malignant solid tumors that have a genetic change (mutation) in CKIT or PDGFRA and have spread to nearby tissue or lymph nodes (locally advanced) or other places…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT04771520
- Testing
- Avapritinib
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer, Histiocytic Neoplasm
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer…
- Conditions
- Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
- Trial name
- NCT05786924
- Testing
- S241656, FOLFOX6/FOLFOX7, FOLFIRI
- Where
- 49 sites in United States, Australia and 8 more
- Volunteers
- 554 people
- Sponsor
- Institut de Recherches Internationales Servier
Cancer, Solid Tumor
Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)
The present study has 5 parts. In Parts A and A1, the dose of intravenous (IV) pembrolizumab (MK-3475) will be escalated from 1 to 10 mg/kg to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for…
- Trial name
- KEYNOTE-001 (NCT01295827)
- Testing
- Pembrolizumab
- Volunteers
- 1,260 people
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasms, Liver, Neoplasms Malignant
Clinical Application of Super-resolution Ultrasound(SR-US) Imaging in Solid Tumors
It has well accepted that tumor angiogenesis present aberrant vascular architecture and functional abnormalities, which is associated with tumorigenesis, tumor propagation and progression.
- Conditions
- Neoplasms, Liver, Neoplasms Malignant, Neoplasm Metastasis, Ultrasound
- Trial name
- NCT06018142
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
NSCLC, Breast Cancer
A Study of YL202 in Selected Patients With Advanced Solid Tumors
This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in the following selected patients with advanced solid tumors.
- Conditions
- NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors
- Trial name
- NCT06107686
- Testing
- YL202 should be intravenously infused
- Where
- 82 sites in China
- Volunteers
- 200 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Solid Tumor, Lymphoma
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas
The potency of immune checkpoint blockade is limited in most solid malignancies, one possible reason for which is tumor microenvironment.
- Trial name
- NCT04407741
- Testing
- SHR2554+SHR1701, SHR1701
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.